Abstrato

The efficacy of butylphthalide soft capsules combined with donepezil tablet in patients with alzheimer disease and its effect on Serum A beta, GSH-Px and SOD

Yiquan Zhang, Huihua Dong, Xianghe Liu & Ming Huang

Objective: To investigate the efficacy of Butylphthalide Soft Capsules combined with donepezil tablet in patients with Alzheimer disease (AD) and its effect on serum amyloid beta (Aβ), glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) and inflammatory cytokines.

Methods: A total of 104 patients with AD enrolled in our hospital from January 2015 to January 2017 were selected as the subjects. According to the random number table, they were divided into observation group and control group, 52 cases in each group. Patients in both groups were given conventional treatment. On such basis, the control group were given oral medication of donepezil each day, besides which, the observation group were treated with Butylphthalide Soft Capsules. The clinical efficacy and adverse reactions in the 2 groups were observed and the levels of serum Aβ, GSH-Px, SOD and inflammatory cytokines (IL-1β, IL-6 and TNF-α), as well as the changes in the cognitive function and the activity of daily living were compared between the two groups before and after treatment.

Results: Before treatment, there was no statistically significant difference between the 2 groups in the levels of serum Aβ, GSH-Px and SOD (P>0.05), while after treatment, the Aβ level in the 2 groups was significantly lower than that before treatment (P<0.05), obviously lower in the observation group than in the control group (P<0.05), and the GSH-Px and SOD levels in the 2 groups were significantly higher than those before treatment (P<0.05), obviously higher in the observation group than in the control group (P<0.05). Before treatment, there was no significant difference in the levels of IL-1β, IL-6 and TNF-αbetween the 2 groups (P>0.05), while after treatment, the levels of IL-1β, IL-6 and TNF-αin the 2 groups were significantly lower than those before treatment (P<0.05), obviously lower in the observation group than in the control group (P<0.05). Before treatment, there was no significant difference in the scores of the mini-mental state examination (MMSE) and ADL between the 2 groups (P>0.05), while after treatment, the scores of MMSE and ADL in the 2 groups were significantly higher than those before treatment (P<0.05), obviously higher in the observation group than in the control group (P<0.05). The total effective rate of the observation group was 94.23%, which was significantly higher than that of the control group (76.92%), and the difference was statistically significant (P<0.05). During treatment the incidence of adverse reactions in the control group was 9.62%, higher than that in the observation group, that was 7.69%, but the difference was not statistically significant.

Conclusion: The treatment of Butylphthalide Soft Capsules with donepezil tablet leads to few side effects and can improve the levels of serum Aβ, GSH-Px and SOD, reduce inflammatory cytokines and enhance cognitive function as well as the activities of daily living in patients with AD, thus worthy of clinical application.